New combo therapy aims to halt liver damage from hepatitis b
Disease control
Not yet recruiting
This study tests whether adding peginterferon alfa-2b to standard antiviral drugs can improve liver health in people with compensated hepatitis B cirrhosis. About 30 adults will be randomly assigned to receive either the combination or antivirals alone. The main goal is to see if…
Phase: NA • Sponsor: Xiamen Humanity Hospital • Aim: Disease control
Last updated May 17, 2026 09:08 UTC